ALUMIS INC. (ALMS)
D
Pipeline Grade
Financial Position (from SEC Filings)
$65.3M
Cash & Equivalents
$87.1M
Quarterly Burn Rate
2 mo
Est. Cash Runway
$3,609M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-01 | Phase2 Readout | — |
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05966480 | Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus | PHASE2 | Active Not Recruiting | 408 |
| NCT05739435 | Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis | PHASE2 | Active Not Recruiting | 165 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-29 | 8-K | ALUMIS INC. (ALMS) (CIK 0001847367) - EXHIBIT 99.1 | EDGAR |